$5,12
▲ +$0,23
(+4,70%)
Vol. 108K
4
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$60.7M
ROE
-322,2%
Margine
-14250,5%
D/E
636,05
Beta
0,80
52W
$2–$14
Consenso Wall Street
12 analisti · Apr 20262
Acquisto forte
9
Compra
1
Mantieni
0
Vendi
0
Vendita forte
91,7%
Rating Compra
Grafico dei Prezzi
Titoli simili
Utili
Tasso di battuta: 25,0%| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Dic 2025 | $-0,60 | $-0,88 | $-0,28 |
| Set 2025 | $-0,59 | $-0,85 | $-0,26 |
| Giu 2025 | $-0,48 | $-0,78 | $-0,30 |
| Mar 2025 | $-0,97 | $-0,09 | +$0,88 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Ricavi | — | $91K | $81K | $27K | $15K | $77K |
| Utile netto | — | -$13.5M | -$751K | -$7.4M | -$8.8M | -$9.2M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -322.2% | -322.2% | -322.2% | -322.2% | -322.2% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -27477.8% | -10386.4% | -10386.4% | -10386.4% | -10386.4% | -14250.5% |
| Gross Margin | 100.0% | 80.4% | 80.4% | 80.4% | 80.4% | 82.2% |
| D/E Ratio | — | 636.05 | 636.05 | 636.05 | 636.05 | 636.05 |
| Current Ratio | 1.58 | 1.58 | 1.58 | 1.58 | 1.58 | 1.53 |
Rapporti chiave
ROA (TTM)
-125,6%
P/S (TTM)
283,46
P/B
2,8
EPS (TTM)
$-3,33
CF/Share
$-0,43
Crescita ricavi 3A
-22,0%
52W High
$13,50
52W Low
$2,28
$2,28
Intervallo 52 settimane
$13,50
Salute finanziaria
Flusso di cassa libero
-$4.8M
Debito netto
$16.5M
Liquidità
$5.2M
Debito totale
$21.7M
Aggiornato al Dic 31, 2025
Як CLNN виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка CLNN vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
283,5
▲
2106%
sopra
peer
(12,9)
vs Peer
vs Settore
Più costoso
P/B
2,8
▲
16%
sopra
peer
(2,5)
vs Peer
vs Settore
Più costoso
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість CLNN vs аналоги Biotechnology
ROE
-322,2%
▼
379%
sotto
peer
(-67,3%)
vs Peer
vs Settore
Debole
Net margin
-14250,5%
▼
4870%
sotto
peer
(-286,8%)
vs Peer
vs Settore
Debole
Валова маржа
82,2%
▲
5%
sopra
peer
(78,6%)
vs Peer
vs Settore
Debole
ROA
-125,6%
▼
169%
sotto
peer
(-46,7%)
vs Peer
vs Settore
Debole
Фінансове здоровʼя CLNN vs аналоги Biotechnology
D/E ratio
636,1
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito alto
Поточна ліквідність
1,5
▼
66%
sotto
peer
(4,4)
vs Peer
vs Settore
Liquidità bassa
Beta
0,8
▼
17%
sotto
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів CLNN
CLNN
Mediana peer
Industria
CLNN прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
CLNN vs аналоги: ключові метрики
Attività insider
NeutralAcquisti
0
Vendite
0
UGWUMBA CHIDOZIE
Beneficial Owner of more than… · Mar 26
17909 shs
UGWUMBA CHIDOZIE
Beneficial Owner of more than… · Feb 03
5559 shs
UGWUMBA CHIDOZIE
Beneficial Owner of more than… · Feb 02
24770 shs
UGWUMBA CHIDOZIE
Beneficial Owner of more than… · Gen 28
19274 shs
UGWUMBA CHIDOZIE
Beneficial Owner of more than… · Gen 23
18221 shs
UGWUMBA CHIDOZIE
Beneficial Owner of more than… · Gen 21
32474 shs
UGWUMBA CHIDOZIE
Beneficial Owner of more than… · Gen 15
58289 shs
MOSCA ALISON
Director · Gen 13
16667 shs
MATLIN DAVID J.
Director · Gen 13
33333 shs
UGWUMBA CHIDOZIE
Beneficial Owner of more than… · Gen 12
44975 shs
Ultimo 90 giorni
Principali azionisti
Top 5: 13,43%SymBiosis Capital Partners,…
6,54%
$3.6M
Scoggin Management, LP
2,33%
$1.3M
Vanguard Group Inc
1,89%
$1.0M
Boxer Capital Management, L…
1,70%
$941K
Ensign Peak Advisors, Inc
0,97%
$539K
Aggiornato al Dic 31, 2025
Ultime notizie
Nessuna notizia correlata ancora